Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Erik L. Kimble & Ryan D. Cassaday. (2021) Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. Leukemia & Lymphoma 62:14, pages 3333-3347.
Read now
Read now
Lidia Gatto, Enrico Franceschi, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi & Alba Ariela Brandes. (2021) Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Review of Anticancer Therapy 21:12, pages 1333-1353.
Read now
Read now
Articles from other publishers (31)
Rushin Patel, Mrunal Patel, Fehmida Laxmidhar, Khushboo Lakhatariya, Darshil Patel, Zalak Patel & Safia Shaikh. (2023) Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-cell Therapy: A Retrospective Study Analyzing Risks, Outcomes, and Healthcare Burden. Cureus.
Crossref
Crossref
Christina Kazzi, Valeriya Kuznetsova, Pakeeran Siriratnam, Sarah Griffith, Shu Wong, Constantine S. Tam, Rubina Alpitsis, Andrew Spencer, Terence J. O'Brien, Charles B. Malpas & Mastura Monif. (2023) Cognition following chimeric antigen receptor T-cell therapy: A systematic review. Journal of Autoimmunity 140, pages 103126.
Crossref
Crossref
Qingxia Liu, Qifeng Song, Cheng Luo, Jian Wei, Yao Xu, Liwen Zhao & Yong Wang. (2023) A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma. Molecular Immunology 162, pages 125-132.
Crossref
Crossref
Antonio Pontoriero, Paola Critelli, Federico Chillari, Giacomo Ferrantelli, Miriam Sciacca, Anna Brogna, Silvana Parisi & Stefano Pergolizzi. (2023) Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors—A Narrative Review. Journal of Personalized Medicine 13:8, pages 1261.
Crossref
Crossref
Tahereh Hojjatipour, Zahra Sharifzadeh, Amirhosein Maali & Mehdi Azad. (2023) Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells. Human Cell 36:6, pages 1843-1864.
Crossref
Crossref
Peizhen Geng, Yuhua Chi, Yuan Yuan, Maoquan Yang, Xiaohua Zhao, Zhengchun Liu, Guangwei Liu, Yihui Liu, Liang Zhu & Shuai Wang. (2023) Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Aditi Mulgaonkar, Durga Udayakumar, Yaxing Yang, Shelby Harris, Orhan K. Öz, Praveen Ramakrishnan Geethakumari & Xiankai Sun. (2023) Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy. Frontiers in Medicine 10.
Crossref
Crossref
Lidia Gatto, Ilaria Ricciotti, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini, Lucia Ranieri & Enrico Franceschi. (2023) CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap. Frontiers in Oncology 13.
Crossref
Crossref
Sofie Seghers, Laure-Anne Teuwen, Michiel Beyens, Dennis De Blick, Vito Sabato, Didier G. Ebo & Hans Prenen. (2023) Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist. Cancer Treatment Reviews 116, pages 102559.
Crossref
Crossref
Giada Del Baldo, Francesca Del Bufalo, Claudia Pinacchio, Andrea Carai, Concetta Quintarelli, Biagio De Angelis, Pietro Merli, Antonella Cacchione, Franco Locatelli & Angela Mastronuzzi. (2023) The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors. Frontiers in Immunology 14.
Crossref
Crossref
Jez Huang, Ying Betty Li, Claudie Charlebois, Tina Nguyen, Ziying Liu, Darin Bloemberg, Ahmed Zafer, Ewa Baumann, Caroline Sodja, Sonia Leclerc, Gwen Fewell, Qing Liu, Balabhaskar Prabhakarpandian, Scott McComb, Danica B. Stanimirovic & Anna Jezierski. (2022) Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies. Fluids and Barriers of the CNS 19:1.
Crossref
Crossref
Matthew Foster, Yonatan Negash, Leslie Eberhardt, Wilson W. Bryan, Kimberly Schultz, Xiaofei Wang, Yuan Xu & Bindu George. (2022) Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project. Molecular Therapy - Oncolytics 27, pages 182-194.
Crossref
Crossref
Lanlan Zhou, Nanzhou Yu, Tongjuan Li, Hongyan Ji, Lijun Jiang, Di Wang, Bin Xu & Xiaoxi Zhou. (2022) Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia. Frontiers in Oncology 12.
Crossref
Crossref
Yongxian Hu, Yali Zhou, Mingming Zhang, Houli Zhao, Guoqing Wei, Wengang Ge, Qu Cui, Qitian Mu, Gong Chen, Lu Han, Tingting Guo, Jiazhen Cui, Xiaoyan Jiang, Xiujun Zheng, Shuhui Yu, Xiaolong Li, Xingwang Zhang, Mingxi Chen, Xiuju Li, Ming Gao, Kang Wang, Cheng Zu, Hao Zhang, Xiaohong He, Yanbin Wang, Dongrui Wang, Jiangtao Ren & He Huang. (2022) Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Research 32:11, pages 995-1007.
Crossref
Crossref
Nathalie Scholler, Regis Perbost, Frederick L. Locke, Michael D. Jain, Sarah Turcan, Corinne Danan, Edmund C. Chang, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jenny J. Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M. Rossi, Adrian Bot & Jérôme Galon. (2022) Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nature Medicine 28:9, pages 1872-1882.
Crossref
Crossref
Christopher W. Mount & Luis Nicolas Gonzalez Castro. (2022) Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors. Antibodies 11:2, pages 31.
Crossref
Crossref
Thien Nguyen, Sabine Mueller & Fatema Malbari. (2022) Review: Neurological Complications From Therapies for Pediatric Brain Tumors. Frontiers in Oncology 12.
Crossref
Crossref
Håkon Reikvam, Kimberley Joanne Hatfield, Øystein Wendelbo, Roald Lindås, Philippe Lassalle & Øystein Bruserud. (2022) Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules 12:4, pages 492.
Crossref
Crossref
Lakshmi Nayak & Tracy T. Batchelor. (2022) How I treat neurologic complications in patients with lymphoid cancer. Blood 139:10, pages 1469-1478.
Crossref
Crossref
Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin & Nancy L. Bartlett. (2022) Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology 40:5, pages 481-491.
Crossref
Crossref
Daniel Thomas Ginat. 2022. Neuroimaging Pharmacopoeia. Neuroimaging Pharmacopoeia
215
216
.
Erica L. Heipertz, Evan R. Zynda, Tor Espen Stav-Noraas, Andrew D. Hungler, Shayne E. Boucher, Navjot Kaur & Mohan C. Vemuri. (2021) Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies. Frontiers in Immunology 12.
Crossref
Crossref
Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Meng Wu, Feier Feng, Xin Leng, Tingting Du, Feifei Qi, Xuelian Hu, Yanping Ding, Xin-an Lu, Yuqin Song & Jun Zhu. (2021) Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies. BMC Cancer 21:1.
Crossref
Crossref
Xiaoyue Cui, Rui Liu, Lian Duan, Dan Cao, Qiaoling Zhang & Aijie Zhang. (2021) CAR‐T therapy: Prospects in targeting cancer stem cells. Journal of Cellular and Molecular Medicine 25:21, pages 9891-9904.
Crossref
Crossref
Anat Globerson Levin, Isabelle Rivière, Zelig Eshhar & Michel Sadelain. (2021) CAR T cells: Building on the CD19 paradigm. European Journal of Immunology 51:9, pages 2151-2163.
Crossref
Crossref
Amer Assal & Markus Y. Mapara. (2021) Janus Kinase Inhibitors and Cell Therapy. Frontiers in Immunology 12.
Crossref
Crossref
May Daher, Luciana Melo Garcia, Ye Li & Katayoun Rezvani. (2021) CAR‐NK cells: the next wave of cellular therapy for cancer. Clinical & Translational Immunology 10:4.
Crossref
Crossref
Olaf Penack & Christian Koenecke. (2020) Complications after CD19+ CAR T-Cell Therapy. Cancers 12:11, pages 3445.
Crossref
Crossref
Alexander Michels, Jessica Hartmann & Christian J. Buchholz. (2020) Chimäre Antigenrezeptoren (CARs) in der Onkologie: eine Übersicht zu klinischer Anwendung und neuen EntwicklungenChimeric antigen receptors in oncology: clinical applications and new developments. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 63:11, pages 1331-1340.
Crossref
Crossref
Caroline Diorio, Pamela A. Shaw, Edward PequignotAlena Orlenko, Fang ChenRichard Aplenc, David M. BarrettHamid Bassiri, Edward BehrensAmanda M. DiNofiaVanessa GonzalezNatalka KoterbaBruce L. Levine, Shannon L. MaudeNuala J. Meyer, Jason H. MooreMichele PaesslerDavid L. PorterJenny L. Bush, Don L. SiegelMegan M. Davis, Donglan Zhang, Carl H. JuneStephan A. Grupp, J. Joseph Melenhorst, Simon F. LaceyScott L. Weiss & David T. Teachey. (2020) Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Advances 4:20, pages 5174-5183.
Crossref
Crossref
Marco Cerrano, Marco Ruella, Miguel-Angel Perales, Candida Vitale, Danilo Giuseppe Faraci, Luisa Giaccone, Marta Coscia, Molly Maloy, Miriam Sanchez-Escamilla, Hesham Elsabah, Afraa Fadul, Enrico Maffini, Gianfranco Pittari & Benedetto Bruno. (2020) The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Frontiers in Immunology 11.
Crossref
Crossref